HSC Exam Practice

Sample response. A qualified judgement is a conclusion that is supported but not absolute. It uses conditional language (e.g. "to a large extent", "in some contexts", "provided that") and explicitly names the conditions and limitations under which the conclusion holds.

Marking notes. 1 mark for identifying that a conclusion is still reached (it is not refusal to conclude); 1 mark for naming conditional language or stating that limits / conditions are explicit.

Sample response. (1) State the benefit — identify the biological or social problem the technology may help solve. (2) State the risk or limitation — welfare, environmental, ownership, access or uncertainty. (3) Identify stakeholders — who benefits, who carries risk, and whether the distribution is fair. (4) Include biodiversity — specify whether genetic, species or ecosystem diversity is supported, reduced or altered. (5) Conclude conditionally — judge to what extent benefit outweighs risk, and under what conditions.

Marking notes. 3 marks for naming all five steps in order; 2 marks for any four steps; 1 mark for any three steps; 0 for fewer.

Sample response. Genetic diversity, species diversity and ecosystem diversity.

Marking notes. 2 marks for all three named; 1 mark for two of the three; 0 for one or zero.

Sample response. A biodiversity-effect question asks specifically whether genetic, species or ecosystem diversity is preserved, reduced or altered. A productivity-only response answers a different question — how much output the technology generates — and so leaves the actual question unaddressed. It also misses the trade-off built into many biotechnologies (e.g. high yield achieved by planting one genetically uniform cultivar reduces on-farm genetic diversity, creating monoculture-resistance risks that the productivity figure hides). For a band 4–5 mark, the answer must show that yield can rise while biodiversity falls.

Marking notes. 1 mark for identifying that biodiversity questions require an answer at one of three specific levels; 1 mark for identifying that yield does not address that level; 1 mark for showing the productivity / biodiversity trade-off explicitly (e.g. monoculture or resistance evolution).

Sample response. An absolute conclusion makes a one-sided, unconditional claim — for example: "Biotechnology always benefits society more than it harms it." A qualified conclusion supports a position but explicitly names conditions and limits — for example: "Biotechnology can be highly beneficial in some contexts, but its overall value depends on trade-offs involving risk, biodiversity and stakeholder impact." A qualified conclusion is rewarded because it reflects the comparative, evidence-based evaluation required at Band 5–6.

Marking notes. 1 mark for distinguishing absolute (no conditions) from qualified (conditional, contextual). 1 mark for a valid absolute-style example in biotechnology. 1 mark for a valid qualified-style example using conditional language ("to a large extent", "provided that", "depends on…").

Sample response (a). The largest net benefit is recombinant insulin (benefit 85, cost 15, net +70). The smallest is Bt cotton (benefit 60, cost 70, net −10). [Accept any equivalent reasoning that quotes at least one figure from each.]

Sample response (b). Both insulin and CRISPR sickle-cell therapy deliver direct medical benefit, but Card 2 of the lesson identifies access, cost, safety and consent as the main evaluation issues for medical biotechnology. Recombinant insulin is a long-established therapy with a well-characterised safety profile and relatively accessible cost; CRISPR sickle-cell therapy is currently very expensive (limiting access), and somatic gene-editing carries off-target editing risks (safety) and complex consent issues. These are the reasons its biodiversity / stakeholder-cost score (≈45) is higher than insulin's (≈15) even though the direct benefit is higher.

Sample response (c). Bt cotton's cost (70) exceeds its benefit (60) because monoculture planting of one transgenic cotton line reduces on-farm allelic diversity at the genetic level in the crop. This drives the evolution of Bt-resistant pest strains, which erodes the benefit over time; ownership of patented seed also creates smallholder-farmer dependence. The combination of genetic-level diversity loss and unequal stakeholder impact pushes the cost score above the benefit score in the stylised data.

Marking notes. Part (a) — 1 mark for correct identification of largest and smallest net benefit; 1 mark for quoting at least one supporting figure. Part (b) — 1 mark for invoking the medical-biotech category from Card 2; 1 mark for naming at least one of access/cost/safety/consent and tying it to the score difference. Part (c) — 1 mark for naming genetic-level diversity loss in the crop; 1 mark for naming at least one further issue (resistance evolution OR ownership/stakeholder fairness); 1 mark for explicitly linking these to the cost > benefit pattern in the data.

Sample response. Whether biotechnology benefits society without compromising biodiversity depends on the specific case and context. A strong evaluation applies the five-step framework — benefit, risk, stakeholders, biodiversity level, qualified judgement — to each case before synthesising.

Medical case — CRISPR therapy for sickle-cell disease. Benefit: curative replacement of dysfunctional haemoglobin in patients. Risks: off-target editing (safety), multi-million-dollar treatment cost (access). Stakeholders: patients, public health systems, insurers — distribution currently inequitable. Biodiversity: negligible at the population biodiversity level because the edit is somatic and not heritable. Qualified judgement: to a large extent beneficial provided that access is broadened and safety profiles mature.

Agricultural case — Bt cotton. Benefit: reduced bollworm damage and reduced broad-spectrum pesticide use. Risks: pest evolution of Bt-resistance, seed ownership concentrated on a single supplier, smallholder farmer dependence. Stakeholders: smallholder farmers, seed companies, consumers, non-target invertebrate communities. Biodiversity: at the genetic level within the crop, allelic diversity is reduced; at the species/ecosystem level, monoculture and altered pesticide use affect non-target invertebrates. Qualified judgement: beneficial in many contexts but the biodiversity trade-off is real unless diversity is maintained at the farm and landscape scale.

Animal / conservation case — CRISPR-based gene drive against invasive black rats. Benefit: recovery of native seabird species — a biodiversity benefit. Risks: drive escape to non-target populations, irreversibility, animal welfare. Stakeholders: conservation agency, neighbouring fisheries, indigenous landowners. Biodiversity: positive at the species and ecosystem level on the target island; potentially catastrophic at the same level if the drive escapes. Qualified judgement: justified on the island provided that escape pathways are eliminated, reversibility is engineered, and stakeholders are consulted.

Comparative synthesis. The three cases produce three different balances of benefit and risk. A single universal verdict is therefore unjustified. To a large extent biotechnology can benefit society without compromising biodiversity in medical applications provided that access is fairly distributed; in agricultural applications its value depends on whether genetic-level diversity is maintained; in conservation applications it can actively support biodiversity provided that escape and irreversibility risks are managed. The overall judgement must be conditional and case-by-case.

Marking notes. 1 mark — applies the five-step framework explicitly or uses it as the organising spine. 1 mark — medical case: named example (e.g. CRISPR-SCD, recombinant insulin) with a specified biodiversity-level statement. 1 mark — agricultural case: named example (e.g. Bt cotton, GM canola, Golden Rice) with a named risk (resistance / monoculture / ownership) AND the biodiversity level identified. 1 mark — animal / conservation case: named example (e.g. gene drive, transgenic livestock, cloned animals) with at least one stakeholder identified. 1 mark — explicit stakeholder analysis (who benefits / who carries risk) appears at least once. 1 mark — comparative synthesis paragraph shows the three cases produce different balances (not one universal verdict). 1 mark — final judgement uses explicit conditional language consistent with Card 4 ("to a large extent", "provided that"). 1 mark — final judgement is per-context (not collapsed across all three cases). 1 mark — precise lesson terminology used throughout (synthesis, qualified judgement, stakeholder, biodiversity level, trade-off).